| Literature DB >> 24472538 |
Hyeon-Ok Jin1, Yun-Han Lee2, Jin-Ah Park1, Jin-Hee Kim1, Sung-Eun Hong3, Hyun-Ah Kim4, Eun-Kyu Kim4, Woo Chul Noh4, Byung-Hak Kim5, Sang-Kyu Ye5, Yoon Hwan Chang6, Seok-Il Hong6, Young-Joon Hong6, In-Chul Park7, Jin Kyung Lee8.
Abstract
The PI3K/Akt/mTOR axis in lung cancer is frequently activated and implicated in tumorigenesis. Specific targeting of this pathway is therefore an attractive therapeutic approach for lung cancer. However, non-small cell lung cancer cells are resistant to BEZ235, a dual inhibitor of PI3K and mTOR. Interestingly, blockage of Stat3 with a selective inhibitor, S3I-201, or siRNA dramatically sensitized the BEZ235-induced cell death, as evident from increased PARP cleavage. Furthermore, inhibition of Stat3 led to enhancement of cell death induced by LY294002, a PI3K inhibitor. Treatment of cells with a combination of BEZ235 and S3I-201 significantly induced the proapoptotic transcription factor, CHOP, and its targets, Bim and DR4. Knockdown of CHOP or Bim suppressed cell death stimulated by the combination treatment, implicating the involvement of these BEZ235/S3I-201-induced factors in pronounced cell death. Moreover, the BEZ235/S3I-201 combination enhanced TRAIL-induced cell death. Our results collectively suggest that blockage of Stat3 presents an effective strategy to overcome resistance to PI3K/Akt/mTOR inhibition.Entities:
Keywords: Akt; Bim; CHOP; PI3K; Stat3; mTOR
Mesh:
Substances:
Year: 2014 PMID: 24472538 DOI: 10.1016/j.bbrc.2014.01.086
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575